Oppenheimer Asset Management Inc. Has $5.66 Million Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Oppenheimer Asset Management Inc. raised its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 14.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 37,576 shares of the medical research company's stock after purchasing an additional 4,671 shares during the period. Oppenheimer Asset Management Inc. owned 0.08% of Charles River Laboratories International worth $5,656,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. D1 Capital Partners L.P. bought a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $172,752,000. Assenagon Asset Management S.A. lifted its position in Charles River Laboratories International by 1,721.1% in the first quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company's stock worth $85,811,000 after purchasing an additional 538,792 shares during the period. Norges Bank acquired a new stake in Charles River Laboratories International in the fourth quarter worth approximately $98,886,000. Wellington Management Group LLP lifted its position in Charles River Laboratories International by 9.0% in the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after purchasing an additional 335,658 shares during the period. Finally, Nomura Holdings Inc. acquired a new stake in Charles River Laboratories International in the fourth quarter worth approximately $56,820,000. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Down 1.1%

Shares of CRL traded down $1.68 during mid-day trading on Friday, reaching $149.91. The company's stock had a trading volume of 814,656 shares, compared to its average volume of 1,024,364. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.78. The company has a market cap of $7.36 billion, a price-to-earnings ratio of -230.64, a price-to-earnings-growth ratio of 5.08 and a beta of 1.48. The business has a fifty day moving average of $136.13 and a 200 day moving average of $153.68.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The business had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. During the same period in the prior year, the business posted $2.27 earnings per share. Charles River Laboratories International's revenue for the quarter was down 2.7% compared to the same quarter last year. As a group, analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on CRL shares. Evercore ISI upgraded Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price for the company in a research report on Thursday, May 8th. Barclays upped their target price on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. Wall Street Zen downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Friday. Mizuho cut their target price on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. Finally, The Goldman Sachs Group downgraded Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their target price for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $171.85.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president now directly owns 19,513 shares of the company's stock, valued at approximately $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.30% of the stock is currently owned by company insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).